Skip to main content

rexahn-pharma-2019-logo

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/683,408, “Fluorocyclopentenylcytosine Methods of Use.” The patent application covers the use of RX-3117 in a broad range of tumor types that over-express UCK2, the enzyme that activates RX-3117. The company expects the patent to be issued within a few months from the notice of allowance and provide protection to 2036. 

{iframe}https://investors.rexahn.com/press-releases/detail/291/rexahn-receives-notice-of-allowance-for-u-s-patent{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.